STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [8-K] Guardant Health, Inc. Reports Material Event

CMO Craig Eagle to leave Guardant Health (NASDAQ: GH) May 8

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Guardant Health, Inc. disclosed that its Chief Medical Officer, Craig Eagle, M.D., has resigned. His resignation is scheduled to take effect on May 8, 2026. The company reported this leadership change in a current report signed by its Chief Legal Officer and Corporate Secretary, John G. Saia.

Positive

  • None.

Negative

  • None.

Insights

Guardant Health reports upcoming CMO change without further disclosed details.

Guardant Health announced that Chief Medical Officer Craig Eagle, M.D., has resigned, effective May 8, 2026. The filing does not provide additional context such as reasons for the departure or succession plans.

For a diagnostics and oncology-focused company, the CMO typically plays a key role in clinical strategy and regulatory interactions. The practical impact of this change will depend on how quickly a successor is named and how the transition is managed, which is not addressed in this disclosure.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Resignation effective date May 8, 2026 Effective date of Chief Medical Officer Craig Eagle’s resignation
Announcement date April 27, 2026 Date Guardant Health disclosed the CMO resignation
Chief Medical Officer financial
"announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
Understanding 8-K Material Events →
NASDAQ false 0001576280 0001576280 2026-04-27 2026-04-27
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 27, 2026

 

 

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38683   45-4139254
(State or other jurisdiction
of incorporation or organization)		   (Commission
File Number)		   (IRS Employer
Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 27, 2026, Guardant Health, Inc. (the “Company”) announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer, to be effective as of May 8, 2026.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GUARDANT HEALTH, INC.
Date: April 27, 2026     By:  

/s/ John G. Saia

      John G. Saia
      Chief Legal Officer and Corporate Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did Guardant Health (GH) disclose in this 8-K?

Guardant Health disclosed that its Chief Medical Officer, Craig Eagle, M.D., has resigned. The company stated that his resignation is effective May 8, 2026, signaling an upcoming change in leadership for its medical and clinical functions.

When is Guardant Health CMO Craig Eagle’s resignation effective?

Craig Eagle, M.D.’s resignation as Chief Medical Officer is effective May 8, 2026. Guardant Health reported the leadership change in a current report dated April 27, 2026, giving a short transition window before the effective date.

Who signed Guardant Health’s disclosure about the CMO resignation?

The disclosure was signed by John G. Saia, Guardant Health’s Chief Legal Officer and Corporate Secretary. His signature indicates the company’s formal authorization of the report detailing Chief Medical Officer Craig Eagle’s resignation effective May 8, 2026.

What is the role of Craig Eagle, M.D. at Guardant Health prior to resignation?

Before his announced resignation, Craig Eagle, M.D. served as Guardant Health’s Chief Medical Officer. This role typically oversees medical, clinical, and scientific strategy, which is particularly important for a healthcare and diagnostics-focused company like Guardant Health.

On what date did Guardant Health announce its CMO’s resignation?

Guardant Health announced the resignation of its Chief Medical Officer, Craig Eagle, M.D., on April 27, 2026. The company’s current report states that the resignation will become effective slightly later, on May 8, 2026.

Filing Exhibits & Attachments

3 documents

Other Documents